Immunovant, Inc. reports recurring developments from a clinical-stage immunology business focused on anti-FcRn therapies for autoimmune diseases. Its news flow centers on IMVT-1402, a potential neonatal Fc receptor inhibitor, and batoclimab, with updates across Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, difficult-to-treat rheumatoid arthritis, Sjögren’s disease, cutaneous lupus erythematosus and thyroid eye disease.
Company updates also cover quarterly operating results, research and development spending, trial design and clinical-study results, safety observations, cash runway, financing activity and shareholder voting matters. Because Immunovant operates in a single research, development and manufacturing segment, recurring disclosures are closely tied to clinical execution, product-candidate manufacturing and capital resources for autoimmune disease programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.